VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25
March 17 2021 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and
full year results for the period ended December 31, 2020 on
Thursday, March 25, 2021 before market open. Professor Dror Harats,
M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer,
will host a conference call at 8:30am ET the same day to discuss
the results and provide a corporate update.
Conference Call:Thursday,
March 25, 2021 at 8:30am ETConference ID:
13717784US: 1 877 407 9208Israel Local: 1 809 406 247International:
1 201-493-6784Webcast:
https://edge.media-server.com/mmc/p/9cahpyse
About VBLVascular Biogenics Ltd., operating
as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is an
investigational, first-in-class, targeted anti-cancer gene-therapy
agent that is being developed to treat a wide range of solid
tumors. VB-111 is currently being studied in a VBL-sponsored Phase
3 registration enabling trial for platinum-resistant ovarian
cancer.
CONTACT:Burns McClellan for VBL
TherapeuticsLee Roth (investors) / Ryo Imai
(media)lroth@burnsmc.com /
rimai@burnsmc.com+1-212-213-0006
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024